Pfizer Beats Estimates as Company Prepares for Split
This article is for subscribers only.
Pfizer Inc.’s two new brand-drug units will operate on a separate basis, reporting independent profits and losses, under the leaders that Chief Executive Officer Ian Read elevated to head them.
The businesses, along with an established products line that could be split from the company after 2017, will report separate results that will show investors how each line of drugs, and the leaders managing them, are performing.